Psychobiotics: An Exciting New Development
Research has shown that the gut has an important supportive role in the prevention and treatment of mental health conditions, making it “the new rainforest” of medicinal foods.
A US patent has been filed in 2018 and published in 2020 for the strain BIFIDOBACTERIUM LONGUM:
Targeting the obesity epidemic, the team will manufacture and launch a probiotic capsule for the UK and Ireland through contract manufacture partners and retail distributors.
Following approximately 1 million euros of commercial- and grant-aided research performed at the APC (see below), the strain is identified, clinically tested and ready for commercialisation through:
Inclusion in probiotic drinks, or other foodstuffs
Having built the firm’s infrastructure and launched the product in UK and Ireland, Psychobiotics will target North America on a regional basis either through a wholly owned subsidiary or a partner in North America, to address the nutritional obesity epidemic and weight-gain aide effects of patietns taking psychotic drugs.
Through ecommerce partners currently being developed, Psychobiotics will distribute capsules through online and bricks and mortar grocery partners in Asia.
Psychobiotics has currently engaged a senior food marketing professional to plan the firm’s market entry strategy.
Psychobiotics is currently in the process of forming a spin out from University College Cork (UCC), expected in Q1 2021, where UCC and the founders will share the firm’s equity.Following this spin out, the firm will raise a seed round of 1.5 million euros to:
- Build marketing materials for online and offline brand building
- Manufacture and package the first capsules for sale through contract manufacturers
- Purchase shelf space in online / offline retail channels
- Engage full operational team to work from incubator space in UCC
APC Microbiome Research Centre
The Alimentary Pharmabiotic Centre (APC) Microbiome research centre is the world’s leading microbiome research institute, where Profs Cryan and Dinan are the leaders in the science of the gut-brain axis. A spin out from the APC, Precision Biotics, based on work done by Profs Cryan and Dinan, was recently acquired by Novozyme for 80 million euros sparking strong investor interest in new APC microbiome spin outs.